Abstract
A low anti-spike antibody response of 28.6% was observed 28 days after BNT162b2 vaccine second dose among 133 solid organ transplant recipients without previous coronavirus disease 2019 (COVID-19). No serious adverse events were recorded. Four severe COVID-19 cases were reported between or after the 2 doses. Our data suggest to change the vaccine strategy.
Keywords: COVID-19 disease; SARS-CoV-2 vaccination; SOT recipients; anti-spike antibodies; humoral response.
All Keywords
【저자키워드】 COVID-19 disease, Humoral response, anti-spike antibodies, SARS-CoV-2 vaccination, SOT recipients, 【초록키워드】 COVID-19, coronavirus disease, SARS-CoV-2, BNT162b2 vaccine, severe COVID-19, Anti-spike, solid organ transplant, humoral, SOT, Serious Adverse Event, second dose, anti-spike antibody response, doses, recipient, reported, the vaccine, were recorded, 【제목키워드】 SARS-CoV-2, coronavirus 2, Transplant, response, respiratory, recipient, Poor,
【저자키워드】 COVID-19 disease, Humoral response, anti-spike antibodies, SARS-CoV-2 vaccination, SOT recipients, 【초록키워드】 COVID-19, coronavirus disease, SARS-CoV-2, BNT162b2 vaccine, severe COVID-19, Anti-spike, solid organ transplant, humoral, SOT, Serious Adverse Event, second dose, anti-spike antibody response, doses, recipient, reported, the vaccine, were recorded, 【제목키워드】 SARS-CoV-2, coronavirus 2, Transplant, response, respiratory, recipient, Poor,
{{{ 추상적인 }}}
2019년 코로나19(COVID-19) 이전에 고형장기이식 환자 133명을 대상으로 BNT162b2 백신 2차 접종 후 28.6%의 낮은 항스파이크 항체 반응이 관찰됐다. 심각한 부작용은 기록되지 않았습니다. 4건의 중증 COVID-19 사례가 2회 투여 사이 또는 투여 후에 보고되었습니다. 우리의 데이터는 백신 전략을 변경할 것을 제안합니다.
{{ 키워드: }} COVID-19 질병; SARS-CoV-2 예방접종; SOT 수혜자; 스파이크 방지 항체; 체액 반응.